GlassScriptPhysician profile
Tanvi R Patel
NPI 1649530395
$1,430.02
in general payments reported to CMS, 2019-2025
15 companies · $312 in 2025
The $312 reported for 2025 was less than what a typical Pediatric Allergy/Immunology provider received nationally (typical 2025 total: $375).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $148 · 2020: $19.33 · 2021: $38.37 · 2022: $327 · 2023: $187 · 2024: $400 · 2025: $312.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $898.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $898.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $221.38 | 2024-2025 | Dupixent |
| Incyte Corporation | $184.14 | 2021-2025 | Opzelura |
| Genzyme Corporation | $160.26 | 2019-2023 | |
| Adma Biomanufacturing LLC | $150.00 | 2024 | |
| E.R. Squibb & Sons, L.L.C. | $123.95 | 2022 | |
| Csl Behring | $90.30 | 2019-2025 | Andembry |
| Ars Pharmaceuticals Operations, INC. | $88.71 | 2025 | Neffy |
| Abbvie INC. | $84.60 | 2022 | |
| Genentech USA, INC. | $76.74 | 2024 | Xolair |
| Kaleo, INC. | $75.00 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $68.85 | 2019-2025 | |
| Pfizer INC. | $42.46 | 2022-2023 | |
| Sun Pharmaceutical Industries INC. | $32.25 | 2024-2025 | |
| Regeneron Pharmaceuticals, INC. | $16.14 | 2023 | Dupixent |
| Shire North American Group INC | $15.24 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tanvi Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.